BrainScope Company, Inc. news

BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it had concluded both algorithm development and clinical validation studies in adolescent and young adult populations using its objective, EEG-based technology. The purpose of the studies was to create and validate an objective, personalized capability for assessment of concussion and readiness to return to activities in males and females between th

BrainScope today announced a new system-wide agreement with Yankee Alliance to make BrainScope’s innovative point-of-care neuro-technology system available to the 18,000 members, including over 5000 outpatient facilities and senior centers, in Yankee Alliance. BrainScope is the only FDA cleared medical device that aids in the objective triage of head injured patients for suspected mild traumatic brain injuries (mTBIs), including brain bleed and concussion. When used by Emergency Departm

Brain-assessment device innovator BrainScope, and Aon plc (NYSE: AON), a leading global professional services firm, today announced the completion of an intellectual property-based funding arrangement. The funding arrangement provides BrainScope with up to $35 million in capital to fund the full expansion of its commercial activities as well as to develop new clinical applications on it

BrainScope today announced the availability of its third groundbreaking FDA-cleared algorithm on the BrainScope device. The Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of patients at baseline, point of injury, and through recovery. The Concussion Index adds to the suite of FDA cleared algorithms already available on the BrainScope device and in clinical use today to rapidly triage suspected mild traumatic brain

JAMA Network Open has published "Validation of a Machine Learning Brain Electrical Activity-Based Index to Aid in Diagnosing Concussion Among Athletes," a ground-breaking study on the accuracy of the BrainScope FDA-cleared biomarker, the Concussion Index, to indicate the likelihood and severity of concussive brain injury and to aid in evaluating an athlete`s readiness to return to play.  

"What this shows us is that for the first time we have a point of care and